Featured Research

from universities, journals, and other organizations

Gabapentin opens window of communication

Date:
June 21, 2010
Source:
Mayo Clinic
Summary:
For patients with quadriplegia, mutism and lower cranial nerve paralysis (locked-in syndrome), their only means of interacting with others is through vertical gaze and upper eyelid movements, using eye-coded communication strategies.

For patients with quadriplegia, mutism and lower cranial nerve paralysis (locked-in syndrome), their only means of interacting with others is through vertical gaze and upper eyelid movements, using eye-coded communication strategies.

Related Articles


In the June issue of Mayo Clinic Proceedings, researchers from Italy describe four patients with locked-in syndrome who also had dancing eye syndrome (opsoclonus-myoclonus syndrome). Because these patients' eyes spontaneously and continuously oscillated in a variety of directions beyond their control, they could no longer interact with family members, physicians or other people.

The lead author, Francesca Pistoia, M.D., University of L'Aquila, Italy, reports that a decision was made to treat these patients with daily continuous gabapentin therapy based on a previous successful experience. Gabapentin was started as a single 300 mg dose on the first day followed by 600 milligrams per day in divided doses on the second day. In two of the patients, this dosage reduced ocular symptoms, and communication and quality of life improved. For the other two patients, the dose was further increased, with the best response achieved with a daily 1,200 mg dose.

In all four patients, attempts to stop treatment resulted in recurrence of dancing eye symptoms six hours after the last dose. Thus, gabapentin use was promptly resumed. Researchers found none of the patients experienced adverse effects from the treatment.

In an accompanying editorial, Joseph Sirven, M.D., Mayo Clinic neurologist, discusses the off-label use of gabapentin, which was approved by the U.S. Food and Drug Administration in 1994 for use as an adjunctive medication to control partial seizures. Dr. Sirven writes, "Ironically, despite the fact that the drug was invented and synthesized for its use in seizure prevention, its smallest market today is epilepsy and seizures."

"The study by Pistoia and colleagues has a potential profound impact for treatment of patients with locked-in syndrome and opsoclonus-myoclonus syndrome," writes Dr. Sirven. "Because this neurologic condition is so rare, small observational studies serve as the main source of clinical evidence and could be the cornerstone for clinical practice with no other evidence."


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Journal References:

  1. F. Pistoia, M. Conson, M. Sara. Opsoclonus-Myoclonus Syndrome in Patients With Locked-in Syndrome: A Therapeutic Porthole With Gabapentin. Mayo Clinic Proceedings, 2010; 85 (6): 527 DOI: 10.4065/mcp.2010.0042
  2. J. I. Sirven. New Uses for Older Drugs: The Tales of Aspirin, Thalidomide, and Gabapentin. Mayo Clinic Proceedings, 2010; 85 (6): 508 DOI: 10.4065/mcp.2010.0267

Cite This Page:

Mayo Clinic. "Gabapentin opens window of communication." ScienceDaily. ScienceDaily, 21 June 2010. <www.sciencedaily.com/releases/2010/06/100616171645.htm>.
Mayo Clinic. (2010, June 21). Gabapentin opens window of communication. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2010/06/100616171645.htm
Mayo Clinic. "Gabapentin opens window of communication." ScienceDaily. www.sciencedaily.com/releases/2010/06/100616171645.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Reuters - Innovations Video Online (Dec. 21, 2014) A team of scientists led by Danish chemist Jorn Christensen says they have isolated two chemical compounds within an existing antipsychotic medication that could be used to help a range of failing antibiotics work against killer bacterial infections, such as Tuberculosis. Jim Drury went to meet him. Video provided by Reuters
Powered by NewsLook.com
Hugging It Out Could Help You Ward Off A Cold

Hugging It Out Could Help You Ward Off A Cold

Newsy (Dec. 21, 2014) Carnegie Mellon researchers found frequent hugs can help people avoid stress-related illnesses. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins